CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY
Abstract
Background. Managing anticoagulant therapy in cancer-associated thrombosis (CAT) remains a clinical challenge, balanced between the heightened risks of recurrent venous thromboembolism (VTE) and major bleeding. The START2 Registry ONCO-VTE provides prospective, real-world evidence from patients with active malignancies, tracking the transition of clinical practice toward direct oral anticoagulants (DOACs). Objectives. This study characterizes the CAT patient population and assesses temporal changes in prescription trends and clinical outcomes by comparing two distinct enrollment windows: January 2022–April 2024 (Group 1) and April 2024–December 2025 (Group 2). Methods. Data from 333 patients (extracted as of Dec. 18, 2025) were analyzed. Group 1 comprised 270 patients, while Group 2 included 63 patients enrolled via the REDCap platform. Primary endpoints focused on anticoagulant selection, VTE recurrence, major bleeding events, and all-cause mortality. Results. The median age of the cohort was 69 years (29% aged ≥75). Over a median follow-up of 12 months (14 months for Group 1; 6 months for Group 2), solid tumors—primarily lung (18%) and colorectal (13%)—were the most prevalent. Deep vein thrombosis was the leading index event (52%), with 35% of all events being incidentally detected. Comorbidities such as hypertension (47%) and cardiovascular disease (11%) were frequent. A clear shift in treatment was observed: DOAC use rose from 59% in Group 1 to 64% in Group 2, while parenteral anticoagulant use (LMWH/Fondaparinux) declined from nearly 40% to 34%. Across the full cohort, VTE recurrence and major bleeding occurred in 7.5% and 6.6% of patients, respectively. In a balanced subgroup analysis (≥6 months follow-up, n=227), Group 2 showed a significant reduction in major bleeding compared to Group 1 (7.1% vs. 11.2%), despite similar VTE recurrence rates (7.1% vs. 8.1%). Conclusions. Analysis of the START2 ONCO-VTE registry highlights a growing preference for DOACs in real-world oncology. This evolution in prescribing patterns is associated with a significant reduction in major bleeding events without loss of antithrombotic protection. These results suggest that modern management strategies provide a high degree of safety and efficacy, even within this fragile patient population.
Related
- Anticoagulant Prophylaxis with Edoxaban for Asymptomatic Isolated Distal Deep Vein Thrombosis in Perioperative Hip Fracture Patients.
- CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY
- Clinical Outcomes After Drug-Eluting Stent Thrombosis in Patients on Hemodialysis ― Insights From the REAL-ST Registry ―
- Comparison of Unfractionated Heparin and Low‐Molecular‐Weight Heparin in Acute Cerebral Venous Thrombosis: A Subanalysis of the CLOT‐VENUS Registry
- Time to first recurrent thrombosis in adults with thrombotic antiphospholipid syndrome: a registry-based retrospective cohort study
BibTeX
@article{marchetti2026co015,
title = {{CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY}},
author = {Marina Marchetti},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/717},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY
AU - Marina Marchetti
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/717
AB - Background. Managing anticoagulant therapy in cancer-associated thrombosis (CAT) remains a clinical challenge, balanced between the heightened risks of recurrent venous thromboembolism (VTE) and major bleeding. The START2 Registry ONCO-VTE provides prospective, real-world evidence from patients with active malignancies, tracking the transition of clinical practice toward direct oral anticoagulants (DOACs). Objectives. This study characterizes the CAT patient population and assesses temporal changes in prescription trends and clinical outcomes by comparing two distinct enrollment windows: January 2022–April 2024 (Group 1) and April 2024–December 2025 (Group 2). Methods. Data from 333 patients (extracted as of Dec. 18, 2025) were analyzed. Group 1 comprised 270 patients, while Group 2 included 63 patients enrolled via the REDCap platform. Primary endpoints focused on anticoagulant selection, VTE recurrence, major bleeding events, and all-cause mortality. Results. The median age of the cohort was 69 years (29% aged ≥75). Over a median follow-up of 12 months (14 months for Group 1; 6 months for Group 2), solid tumors—primarily lung (18%) and colorectal (13%)—were the most prevalent. Deep vein thrombosis was the leading index event (52%), with 35% of all events being incidentally detected. Comorbidities such as hypertension (47%) and cardiovascular disease (11%) were frequent. A clear shift in treatment was observed: DOAC use rose from 59% in Group 1 to 64% in Group 2, while parenteral anticoagulant use (LMWH/Fondaparinux) declined from nearly 40% to 34%. Across the full cohort, VTE recurrence and major bleeding occurred in 7.5% and 6.6% of patients, respectively. In a balanced subgroup analysis (≥6 months follow-up, n=227), Group 2 showed a significant reduction in major bleeding compared to Group 1 (7.1% vs. 11.2%), despite similar VTE recurrence rates (7.1% vs. 8.1%). Conclusions. Analysis of the START2 ONCO-VTE registry highlights a growing preference for DOACs in real-world oncology. This evolution in prescribing patterns is associated with a significant reduction in major bleeding events without loss of antithrombotic protection. These results suggest that modern management strategies provide a high degree of safety and efficacy, even within this fragile patient population.
SN - 2785-5309
ER -